Table 3 Characteristics of the patients at the time of inclusion (Day 0) and comparison of the other variables during the study
|  | Control (n = 30) | Antithrombin (n = 30) | Pvalue |
|---|---|---|---|
Age (years) | 67 ± 17 | 73 ± 15 | 0.174 |
Gender (male/female) | 16/14 | 19/11 | 0.601 |
Sepsis/severe sepsis/septic shock | 10/13/7 | 16/8/6 | 0.266 |
APACHE II | 20.4 ± 7.1 | 21.4 ± 9.2 | 0.638 |
SIRS | 3.0 ± 1.0 | 3.0 ± 0.9 | 0.996 |
SOFA | 7.8 ± 3.4 | 8.5 ± 3.4 | 0.452 |
JAAM DIC | 5.5 ± 1.3 | 5.5 ± 1.6 | 0.858 |
ISTH DIC | 5.2 ± 1.4 | 5.4 ± 1.1 | 0.465 |
Antithrombin (%) | 59.1 ± 6.5 | 61.3 ± 7.5 | 0.219 |
Antithrombin (IU/day) | - | 1752 ± 483 | - |
Gabexate mesilate (yes/no) | 17/13 | 16/14 | 1.000 |
Nafamostat mesilate (yes/no) | 3/27 | 3/27 | 1.000 |
Platelet concentrate (yes/no) | 6/24 | 4/26 | 0.731 |
Packed red blood cells (yes/no) | 11/19 | 8/22 | 0.580 |
Fresh frozen plasma (yes/no) | 5/25 | 1/29 | 0.19 |
Lactate (mmol/L) | 2.85(1.275-5.525) | 1.65(0.975-2.975) | 0.051 |
28-day mortality (%) | 13.3 | 10.0 | 1.000 |
Hospital mortality (%) | 16.7 | 20.0 | 1.000 |